Breakthrough approach for treating mastitis in dairy cows

Amicogen, a biotech company focusing on industrial enzyme production and drug development, has teamed up with Lysando, an innovative biotech company with a background in the development of antimicrobial Artilysin, to address the increasing issue of mastitis in dairy cows caused by multi-resistant bacteria.

Savo Ilic / stock.adobe.com

A company release¹ cites that the overuse of antibiotics in animal husbandry has been causing a rapid increase in multidrug-resistant pathogens. About 70% of all antibiotics produced around the world are used in agriculture, often as preventative measures, which has advanced the spread of resistances.

Mastitis is a bacterial infection of the udder caused by various, often multi-resistant strains of bacteria, and is rapidly spreading, particularly in Asia. This causes animal suffering and a substantial wastage of milk production, resulting in a $20-30 billion annual revenue loss for the dairy industry.¹

Amicogen and Lysando are maximizing their combined expertise to create an innovative treatment that is effective and sustainable, reducing the economic impact of mastitis on farmers while enhancing animal welfare.

“We are excited to partner with Lysando to develop a novel and innovative solution against mastitis in dairy cows,” said Dr Park, CEO of Amicogen, in the release.¹ “This collaboration highlights the growing importance of joining forces in biotech and the potential for innovation to address critical challenges – also in agriculture.”

“Our Artilysin technology has shown great promise in addressing bacterial infections and we believe that this partnership will make a real difference in the fight against mastitis,” added Kerstin Emmrich, PhD, director R&D, Lysando AG.

Reference

Amicogen and Lysando: Novel approach for the treatment of mastitis in dairy cows. News release. Amicogen; Lysando. May 8, 2023. Accessed May 8, 2023. https://www.businesswire.com/news/home/20230508005095/en